Having trouble accessing articles? Reset your cache.

FDA posts ceftaroline briefing documents

FDA said in briefing documents that data for ceftaroline from Forest Laboratories Inc. (NYSE:FRX) supports the product's efficacy

Read the full 184 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE